The short answer is, I don't know.
HNSCC is complicated because it is not one, homogeneous group of cancer cells that cause these types of tumours, so even drug combinations may work well in one setting but not in another.
With regards to the upcoming trial, our drug design and manufacturing protols have been determined by the original Pl trial. If we wanted to trial a new combination, we would have to start anew. If BB-401 ever gets commercialised, the new FDA approval process should make it relatively easy to expand the base of combination drugs we can use.
BLT Price at posting:
20.5¢ Sentiment: None Disclosure: Held
